Big Apple Genomics
A new genome research center is scheduled to open next year between the upscale boutiques on Madison Avenue, creating about 500 new research positions in New York.
In the fall of 2012, the new genomics research center is scheduled to open on Madison Avenue in New York City.
The New York Genome Center (NYGC) will centralize data storage and other resources for 11 local research institutions to improve collaboration in personalized medicine. The center is expected to create about 500 new research jobs and generate economic growth for the city by tapping into the $7.4 billion genomics industry.
In the fall of 2012, the new genomics research center is scheduled to open on Madison Avenue in New York City. Source: New York Genome Center
“When we were approached about the NYGC, we were happy to join,” said Bruce Stillman, president of Cold Spring Harbor Laboratory (CSHL), one of the participating institutes. “Some [of the NYGC partners] are hospitals, and we have a lot of opportunity in integrating technology, which we’re already doing a little bit but hope to do more,” said Stillman.
Each institution brings its unique experience and resources to the collaboration. For example, CSHL will focus on molecular biology, genetics, and cancer research. Since establishing its first Genome Research Center in 1998, the principal strength of the lab has been its clinical applications in diagnostics.
The other participating institutions include Columbia University, Cornell University, The Jackson Laboratory, Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine, New York-Presbyterian Hospital, New York University, North Shore-Long Island Jewish Health System, The Rockefeller University, and Stony Brook University.
For many of these institutions, it won’t be the first time they have worked together. For instance, CSHL has collaborated with Memorial Sloan-Kettering Cancer Center, Columbia University, North Shore-Long Island Jewish Health Systems, and Cornell University on previous research projects. Currently, its collaboration with the New York Presbyterian Hospital involves clinical trials using software algorithms developed by Columbia University researchers to personally identify cancer progressing mutations (1).
Data sharing within this new alliance has the ability to integrate research in DNA diagnosis and find drugs that can treat patients, improve bioanalysis, and promote advancements. The new center will also provide a large high-throughput genome sequencing facility featuring Illumina sequencers for participating institutions, develop new products for hospitals to improve healthcare, and establish new collaborations with pharmaceutical companies.
The $125 million facility was funded by several groups including the Simons Foundation, Carson Family Charitable Trust, and Bloomberg Philanthropies.
Operations will be finalized once the leaders create a strategic plan for the center and enroll a science director in charge of the internal research department.
1. Akavia, U.D., Litvin O., Kim J., Sanchez-Garcia F., Kotliar D., Causton H.C., Pochanard P., Mozes E, Garraway L.A., Pe’er D. An Integrated Approach to Uncover Drivers of Cancer. 2010. Cell. 143:1005-1017.
Palm Beach Research News
- CDC: Coming Flu Season may be severe
- Fit kids = smart kids
- Entering Summer…treating sunburn
- Time Travel Research Study
- Thank you, Peanut Butter
- ‘Female Viagra’: Libido pill Addyi approved by US drug agency
- Fluoride UPDATE
- This protein can block HIV
- What “Unboiling” An Egg Can Mean For Cancer Drug Development
- December 15, 2014 – Collegium Pharmaceutical Submits New Drug Application for Xtampza™ ER (oxycodone extended-release); Its Abuse-Deterrent, Extended-Release Analgesic for the Treatment of Chronic Pain